Powerful riposte, so much so, one could even feel the anger. You must have some deep personal issues with Dr Melrose to even go as far as wishing his ultimate fate in your posts, or to even show such a keen/active interest for someone who discloses no sentiment or shareholding in the company.
Yes, I think the recent investment/funding announcement will be more than adequate to see them through Phase 2, at that stage further funding if needed would be forthcoming as has always been the case. So far they have been ahead of budget and expectations in everything in their lead up to the IND Application.
As for the time frame, it is worth noting that the new Administration is currently slashing the restraints on the FDA regulatory playbook from 9,000 pages to 100 pages in order to get new drugs that actually work directly to the market without having to wait 'many many years'. This is most likely the reason American investors such as The Lind Partners have jumped aboard with their $6M investment/funding package, not bad for a company with only a $6M market cap, I am sure that The Lind Partners did their research before they made that decision, probably even read some of your past posts.
http://edition.cnn.com/2017/03/01/health/trump-fda-slash-restraints/index.html
http://edition.cnn.com/2017/04/04/health/fda-gottlieb-background-qualifications/index.html
Given that the IND Application and the planned start of Phase 1 studies are due over the coming months and the dramatic changes taking place in the FDA, I think that it is all upside from here for this company and many other Biotech Stocks!
(20min delay)